Vanguard Group Inc. Purchases 115,327 Shares of Mirum Pharmaceuticals, Inc. $MIRM

Vanguard Group Inc. grew its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 4.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,540,061 shares of the company’s stock after acquiring an additional 115,327 shares during the quarter. Vanguard Group Inc. owned 5.14% of Mirum Pharmaceuticals worth $114,430,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in MIRM. Federated Hermes Inc. boosted its holdings in Mirum Pharmaceuticals by 9,440.4% in the first quarter. Federated Hermes Inc. now owns 347,366 shares of the company’s stock worth $15,649,000 after acquiring an additional 343,725 shares in the last quarter. Nuveen Asset Management LLC boosted its holdings in Mirum Pharmaceuticals by 46.7% in the fourth quarter. Nuveen Asset Management LLC now owns 722,155 shares of the company’s stock worth $29,861,000 after acquiring an additional 229,746 shares in the last quarter. D. E. Shaw & Co. Inc. bought a new stake in Mirum Pharmaceuticals in the fourth quarter worth $6,507,000. Price T Rowe Associates Inc. MD boosted its holdings in Mirum Pharmaceuticals by 10.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,422,729 shares of the company’s stock worth $58,831,000 after acquiring an additional 138,623 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Mirum Pharmaceuticals by 98.5% in the first quarter. Bank of New York Mellon Corp now owns 246,730 shares of the company’s stock worth $11,115,000 after acquiring an additional 122,402 shares in the last quarter.

Mirum Pharmaceuticals Trading Up 3.5%

Mirum Pharmaceuticals stock opened at $69.06 on Friday. The business has a 50-day simple moving average of $54.37 and a two-hundred day simple moving average of $48.30. The company has a market cap of $3.47 billion, a P/E ratio of -57.07 and a beta of 0.94. Mirum Pharmaceuticals, Inc. has a 52-week low of $36.86 and a 52-week high of $69.27. The company has a quick ratio of 2.97, a current ratio of 3.13 and a debt-to-equity ratio of 1.21.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.19. The business had revenue of $127.79 million during the quarter, compared to the consensus estimate of $107.91 million. Mirum Pharmaceuticals had a negative return on equity of 24.76% and a negative net margin of 13.65%.The business’s quarterly revenue was up 64.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.52) EPS. Analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Analyst Ratings Changes

MIRM has been the topic of several analyst reports. Raymond James Financial reissued a “strong-buy” rating on shares of Mirum Pharmaceuticals in a report on Thursday, August 7th. JMP Securities set a $81.00 target price on Mirum Pharmaceuticals and gave the stock a “market outperform” rating in a report on Thursday, August 7th. Evercore ISI boosted their price target on Mirum Pharmaceuticals from $77.00 to $89.00 and gave the stock an “outperform” rating in a research note on Friday, August 8th. HC Wainwright boosted their price target on Mirum Pharmaceuticals from $73.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday, August 7th. Finally, Wall Street Zen upgraded Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $74.13.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 10,000 shares of the company’s stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $58.00, for a total value of $580,000.00. Following the completion of the sale, the senior vice president owned 2,426 shares in the company, valued at $140,708. This represents a 80.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Christopher Peetz sold 40,000 shares of the company’s stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $62.00, for a total value of $2,480,000.00. Following the completion of the sale, the chief executive officer owned 138,641 shares of the company’s stock, valued at approximately $8,595,742. The trade was a 22.39% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 91,041 shares of company stock valued at $5,320,624. Company insiders own 14.36% of the company’s stock.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.